Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Clarifies Software Link In Abbott COVID-19 Lab Test Recall

Executive Summary

The recall is related to the software’s mixing parameters, which may cause false positives if test samples contaminate each other.

You may also be interested in...



Abbott COVID-19 Lab Test Recall Deemed High-Risk Class I

The recall is related to potential false positives that may occur if a genuine positive test sample overflows into an adjacent sample that would have otherwise tested negative.

Abbott Claims DexCom CGM Suits Renege On Tech-Sharing Agreement

Abbott says DexCom’s patent suits involve technology that was already the subject of a settlement, and raise venue questions.

Device Week, 3 December 2021 – What Do The New Eudamed Modules Mean For Medtech?

In this week’s podcast, EU regulatory editor Amanda Maxwell brings listeners up to speed on the latest news from the European Union, including recent module updates and compliance expectations for the Eudamed database.

Topics

Related Companies

UsernamePublicRestriction

Register

MT144593

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel